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ORIGINAL ARTICLE

D-cycloserine

to enhance extinction of cue-elicited craving for
alcohol: a translational approach
J MacKillop1,2,3, LR Few4, MK Stojek5, CM Murphy5, SF Malutinok5, FT Johnson5, SG Hofmann6, JE McGeary7,8,3, RM Swift3,6 and
PM Monti3
Cue-elicited craving for alcohol is well established but extinction-based treatment to extinguish this response has generated only
modest positive outcomes in clinical trials. Basic and clinical research suggests that D-cycloserine (DCS) enhances extinction to fear
cues under certain conditions. However, it remains unclear whether DCS would also accelerate extinction of cue-elicited craving for
alcohol. The goal of the current study was to examine whether, compared with placebo (PBO), DCS enhanced extinction of cueelicited craving among treatment-seeking individuals with alcohol use disorders (AUDs). Participants were administered DCS
(50 mg) or PBO 1 h before an alcohol extinction paradigm in a simulated bar environment on two occasions. The extinction
procedures occurred 1 week apart and were fully integrated into outpatient treatment. Subjective craving for alcohol was the
primary variable of interest. Follow-up cue reactivity sessions were conducted 1 week and 3 weeks later to ascertain persisting DCS
effects. Drinking outcomes and tolerability were also examined. DCS was associated with augmented reductions in alcohol craving
to alcohol cues during the ﬁrst extinction session and these effects persisted through all subsequent sessions, suggesting
facilitation of extinction. Participants in the DCS condition reported signiﬁcant short-term reductions in drinking, although these did
not persist to follow-up, and found the medication highly tolerable. These ﬁndings provide evidence that DCS enhances extinction
of cue-elicited craving for alcohol in individuals with AUDs in the context of outpatient treatment. The potential clinical utility of
DCS is discussed, including methodological considerations and context-dependent learning.
Translational Psychiatry (2015) 5, e544; doi:10.1038/tp.2015.41; published online 7 April 2015

INTRODUCTION
One major etiological perspective on alcohol and other substance
use disorders is that these are conditions of maladaptive learning,
including molecular, cellular, operant and associative processes.1–4
With regard to associative conditioning, there is extensive
evidence from basic research suggesting that, over time,
conditioned environmental stimuli have an important motivational role.4,5 This is also based on human laboratory studies
indicating that alcohol cues reliably elicit robust increases in
subjective craving6 and, in turn, that craving typically predicts
subsequent alcohol consumption.7,8 Similarly, clinical studies have
revealed that craving, in general and as a function of environmental cues, is associated with relapse.9,10 Although not all studies
support this link, suggesting that the relationship is more complex
than simply cause and effect, craving is considered to have
substantial importance in understanding addictive behavior.11
Accordingly, there has been interest in treatments to weaken
conditioned associations between alcohol cues and cue-elicited
cravings for alcohol. This approach is referred to as cue exposure
treatment (CET) and is akin to exposure with response prevention
approaches in the treatment of anxiety disorders.12,13 Speciﬁcally,
CET exposes patients to alcohol cues under controlled conditions
with the prevention of their dominant response (that is,

consumption). In doing so, the procedure uses extinction to
reduce the contingency between alcohol cues and consumption,
thereby decreasing cue-elicited craving in response to alcohol
cues and, putatively, decreasing the probability of subsequent
drinking. In terms of clinical outcomes, a meta-analysis of the
existing trials of CET suggested limited efﬁcacy,14 although
signiﬁcant heterogeneity of effect size was present, reﬂecting
consistently negative outcomes for nicotine dependence and
consistently positive outcomes for alcohol dependence.15
Pharmacological approaches may enhance the efﬁcacy of CET
and one particularly promising compound is D-cycloserine (D-4amino-3-isoxazolidone; DCS), an antibiotic medication that is also
a partial agonist at the glycine modulatory site at the glutamatergic N-methyl-D-aspartate (NMDA) receptor. NMDA receptors
play a critical role in learning and memory16,17 and DCS may
enhance salutary new learning during therapeutic extinction. This
possibility has been most extensively investigated in augmenting
treatment for anxiety disorders. DCS has been found to enhance
extinction-based treatment of speciﬁc phobia,18 obsessivecompulsive disorder,19 panic disorder20 and social anxiety
disorder.21,22 A recent meta-analysis suggested that, in aggregate,
DCS enhances extinction-based treatment for anxiety disorders,23
although some more recent trials have not revealed signiﬁcant
effects.24
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With regard to alcohol use disorders (AUDs), preclinical studies
have suggested that DCS may enhance extinction to alcohol cues.
Speciﬁcally, DCS has been shown to enhance extinction as
evidenced by reduced reacquisition of alcohol-related conditioned
place preference in mice25 and reduced priming-based reinstatement in rats.26 These ﬁndings are consistent with preclinical
studies on other addictive drugs.27 However, positive effects on
alcohol-related extinction have not been replicated in humans. In
two small studies in which DCS was administered to nontreatment-seeking heavy drinkers, the ﬁrst concluded that DCS
(125 mg) had no signiﬁcant effect on extinction to alcohol cues,28
and the second suggested that DCS (50 mg) resulted in an increase
in craving during the ﬁrst session relative to placebo (PBO).29 To
date, the only investigation conducted in a clinical context was a
small pilot study in which DCS (250 mg) did not have any signiﬁcant
effect when compared with PBO in alcohol-dependent individuals
who had recently completed treatment, albeit with only ﬁve
patients per condition.30 These ﬁndings are similar to the general
literature on DCS and addictive behavior, where the preclinical
literature is relatively robust but ﬁndings in human studies tend to
be mixed.31 For example, one recent study found that DCS
enhanced extinction of cue-elicited craving in nicotine-dependent
individuals,32 whereas another trial with cocaine-dependent
individuals revealed a more persistent increase in craving during
the ﬁrst exposure session in the DCS condition.33
The ambiguity in the literature may be attributable to variability
in important methodological parameters for studying DCS.31,34,35
Unlike conventional pharmacotherapies that are dosed daily,
several critical boundary conditions may be required to be met for
DCS to enhance learning.31,34 For example, high or chronic doses
can cause DCS to act as a direct NMDA antagonist.36–38 Thus, a
week between extinction periods and doses is recommended to
maximize consolidation and to avoid receptor desensitization. The
demonstration of initial cue-elicited craving, which is not present
in all individuals,39,40 is another important parameter as extinction
cannot occur, much less be enhanced, if craving is not elicited in
the ﬁrst place. Finally, a last consideration appears to be treatment
motivation. Analogue studies on DCS using non-treatmentseeking samples and de novo conditioning have yielded null
ﬁndings,41,42 suggesting that DCS effects are only present or are
substantially more robust among clinically affected individuals.
With regard to AUDs, the studies to date have not conducted a
strong test of DCS enhancement of extinction of cue-elicited
craving, meeting the preceding boundary conditions. The primary
goal of the current study was to address these existing limitations
Table 1.

via a translational approach that integrated experimental human
laboratory methods with active treatment in a clinical sample.
Speciﬁcally, we examined whether two administrations of 50 mg
DCS, 1 week apart, would accelerate the attenuation of craving in
a validated extinction paradigm involving 70-min periods of multimodal alcohol cue exposure with response prevention.43,44 This
protocol was implemented in individuals actively seeking treatment for AUDs immediately adjacent to treatment sessions. The
primary hypothesis was that DCS would enhance extinction of
cue-elicited craving for alcohol. In addition, for exploratory
purposes, we also examined its effects on drinking outcomes
and its tolerability.
MATERIALS AND METHODS
Participants
Participants were recruited from the community using advertisements.
Inclusion criteria were: (1) presence of a DSM-IV AUD diagnosis (abuse or
dependence); (2) heavy drinking (that is, ⩾ 14/7 drinks weekly, men/
women45); (3) seeking alcohol treatment; (4) evidence of alcohol cue
reactivity (that is, ⩾ 1 point increase in craving in response to alcohol cues
compared with neutral cues presented in the laboratory); (5) age 21–65
years; (6) stable domicile and contact information; (7) completion of ninth
grade education; and (8) medically appropriate according to physician
examination. Exclusion criteria were: (1) history of severe alcohol
withdrawal symptoms (that is, self-report of hospitalization, hallucinations
or other symptoms of delirium tremens; or in-person evidence of
signiﬁcant withdrawal symptoms at the screening evaluation); (2) a history
of epilepsy/seizures, renal problems or hepatic problems; (3) contraindicated medications (for example, ethionamide, isoniazid, selective
serotonin reuptake inhibitors); (4) presence of other current Axis I
psychiatric disorders, with the exception of nicotine dependence; (5)
living with a participant in the study; (6) mandated to treatment; and (7)
pregnant, nursing or seeking to conceive. In addition to the standard
contraindicated medications, any other medications that the prospective
participants were currently taking were reviewed by the study physician to
determine possible negative interactions.
Thirty-seven participants met eligibility criteria and enrolled in the study.
Participants were randomly assigned to either the DCS condition (n = 19) or
PBO condition (n = 18). The sample size was determined on the basis of
sample sizes in proof-of-concept trials of DCS for anxiety disorders.18,21
One participant was terminated from participation when it was
determined that he was legally restricted from being on the university
campus; four participants were lost to follow-up (DCS = 1, PBO = 3); and
two participants missed one of the critical medication plus extinction
sessions (DCS = 1, PBO = 1), resulting in a ﬁnal sample of 30 (DCS, n = 16;
PBO, n = 14), described in Table 1. A small number of individuals received
an alcohol abuse diagnosis (n = 3), preventing examination of differential

Participant characteristics

Variable

Sex
Age
Education (Years)
Income ($)
Race
Hispanic ethnicity
% Drinking days
% Heavy drinking days
Drinks per day
AUD symptom count
Abuse/dependence
Smoker

P

%/Mean (s.d.)/Median (IQR)
DCS (n = 16)

PBO (n = 14)

63% Male
41.88 (14.90)
14.69 (2.68)
20 000–29 999 (0–9999 to 480 000)
81% White; 13% Black; 6% Mixed Race
6%
83.26% (14.97)
62.28% (28.81)
5.317 (2.81)
5.06 (2.05)
6%/94%
50%

43% Male
42.79 (13)
15.71 (2.37)
30 000–39 999 (10 000–19 999 to 50 000–59 999)
86% White; 14% Black
0%
84.18% (21.09)
70.15% (28.14)
7.870 (6.31)
5.86 (1.96)
14%/86%
64%

0.28
0.86
0.28
0.83
0.63
0.34
0.89
0.46
0.16
0.29
0.46
0.45

Abbreviations: AUD, alcohol use disorder; DCS, D-cycloserine; IQR, interquartile range; PBO, placebo. Continuous variables were examined using t-tests,
categorical variables were examined using χ2 tests; heavy drinking days indicate consuming 5/4 drinks in a given day for males/females. Time frame for
drinking refers to the last 28 days; time frame for AUD symptoms refers to the last year.
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Table 2. General study protocol and alcohol cue reactivity and
extinction protocol
Day Procedure
General protocol
− 4 Telephone screen
− 3 In-person screen
− 2 Blood draw (metabolic panel and drug screen)
− 1 Medical screen
1
Treatment session #1: MET+EXT+DCS/PBO
5
Treatment session #2: MET
8
Treatment session #3: MET+EXT+DCS/PBO
12 Treatment session #4: MET+CR
33 Three-week follow-up: CR
Extinction protocol (days 1 and 8)
Neutral cue exposurea
Acute alcohol cue exposureb
Passive alcohol cue exposurec
Acute alcohol cue exposure
Passive alcohol cue exposure
Acute alcohol cue exposure
Passive alcohol cue exposure
Acute alcohol cue exposure
Passive alcohol cue exposure
Acute alcohol cue exposure
Passive alcohol cue exposure

Duration (Min)
10
120
60
60
240
60
240
60
60
7
7
7
7
7
7
7
7
7
7
7

Abbreviations: CR, acute alcohol cue exposure; within the extinction
protocol, note that all cue exposure and extinction periods were followed
by craving assessments; DCS/PBO, D-cycloserine/placebo; EXT, extinction
(that is, prolonged exposure to alcohol cues with response prevention);
MET, motivational enhancement therapy. aDirect interaction with
water cues. bDirect interaction with participant’s preferred alcoholic
beverage. cPassive observation of participant’s preferred alcoholic beverage.

effects by diagnosis. Of the 30 individuals completing treatment, two were
unavailable for the 3-week follow-up session (DCS = 2, PBO = 0) and three
individuals could not be reached for the telephone debrieﬁng interview
(DCS = 1, PBO = 2).

Study protocol
All procedures were approved by the appropriate institutional review
board and are described in Table 2. Although the study was principally
designed to examine the effects of DCS on extinction of cue-elicited
craving, it was nonetheless registered at clinicaltrials.gov (NCT01362309).
For all visits, participants were required to be sober, veriﬁed via breath
alcohol (Alco-Sensor IV, Intoximeters, St Louis, MO, USA). Initial eligibility
was determined via telephone screen and an in-person screen. The inperson screen included a cue exposure protocol to determine the presence
of cue reactivity. Following the in-person screen, eligible participants had
blood drawn for a standard metabolic panel and assessment of recent
drug use. The study physician (FTJ) conducted a general medical exam and
reviewed the metabolic panel to determine medical eligibility.
Enrolled participants received four sessions of manualized motivational
enhancement therapy over a 2-week period, adapted from the four-session
Project MATCH treatment protocol.46 The extinction protocol was directly
integrated into the treatment protocol and was presented as ‘self-control
training.’ Participants were given a clinical rationale akin to previous trials
of CET: that environmental triggers are known to elicit cravings, that cueelicited craving dissipates over time, and that extended exposure to these
triggers is intended both to personally experience the dissipation of
craving and to make the individual to become less reactive to triggers in
their daily life. The treatment providers were MS-level clinicians (SFM, LRF,
MKS and CMM) who received formal motivational interviewing training
and were supervised by a licensed clinical psychologist (JM). The treatment
was provided in a psychology department outpatient clinic and cue
exposure/extinction sessions were completed in the same building in a
naturalistic bar laboratory environment. Treatment sessions were video
recorded and coded for therapist adherence to the clinical protocol (see
below).

Sessions 1 and 3 included the medication/PBO administration and
extinction procedures, and took place 1 week apart to minimize the
probability of NMDA receptor desensitization. In these sessions, participants ﬁrst received the motivational enhancement therapy sessions in the
clinic and then proceeded to a neutral laboratory room. There, they
received 50 mg DCS or PBO and waited 1 h for medication absorption.
Medication administration was double-blind, with neither experimenters
nor participants having any information about medication status. The
active dose of 50 mg was selected on the basis of previous studies
revealing signiﬁcant effects on enhancement of fear extinction.18,21 Both
active medication and PBO were procured from a custom pharmacy
(Pharmaceutical Specialties; Bogart, GA, USA) and were compounded
with inert ﬁller and 200 mg riboﬂavin to permit veriﬁcation of consumption
via urine ﬂuorescence.47 Active medication and PBO capsules were
identical in all features. Participants were required to not eat for 1 h
before these sessions and had no access to food during the therapy
sessions, meaning that the minimum duration between the last meal and
the extinction protocol was either 3.5 h (session 1) or 3 h (session 3). To
avoid discomfort from hunger, participants were provided with a meal
during the post-extinction period. For smokers, smoking breaks were
provided between the major units of the extended protocol, but not
during aspects that were intended to have continuity (for example, after
motivational enhancement therapy, but not during the extinction
procedure).
Following the 1 h absorption period, participants underwent the 70-min
extinction procedure, with intermittent assessment over the course of the
session (Table 2). This comprised acute exposure to neutral cues (water) in
a neutral laboratory room followed by repeated acute exposures to alcohol
cues (the participant’s preferred alcoholic beverage), in both cases
consisting of visual, tactile, olfactory and proprioceptive stimuli (that is,
picking up the beverage, holding it to one’s nose, and taking deep
inhalations of the smell of the beverage on repeated occasions). The
alcohol portion involved ﬁve acute exposures and ﬁve passive exposure
periods in alternating order (Table 2). That is, participants experienced ﬁve
sequences of actively interacting with their preferred alcoholic beverage
and then passively observing the beverage. All intra-lab cue exposure and
extinction procedures were audiotaped for standardization. Additional
procedural aspects of the medication administration are provided in
supplementary materials.
Session 2 occurred between the two medication administrations,
~ 4 days following the ﬁrst session, and was restricted to motivational
enhancement therapy only. The clinical goal of the session was to follow
up on the participants’ motivation and progress after the extended ﬁrst
session. No cue exposure or extinction procedures were used because it
was too soon to administer the medication again. The fourth session
occurred ~ 4 days after the third session to provide timely follow-up on the
participants’ motivation and progress. A standard cue reactivity procedure
(that is, neutral cues followed by alcohol cues) was used in the fourth
session to assess changes in cue-elicited craving. Finally, a post-treatment
follow-up assessment was completed 3 weeks later and also included a cue
reactivity assessment. The follow-up cue exposure assessments were to
assess the persistence of medication effects on cue-elicited craving.

Assessment
As the primary dependent variable, craving was assessed using a bestpractices approach, deﬁning craving on a continuum of urges/desires48,49
and using a multiple items.50 The items were: ‘How much do you want to
drink alcohol?,’ ‘How much do you crave alcohol?,’ ‘How much do you desire
alcohol?’ and ‘How high is your urge for alcohol?’ and have been successfully
used in previous cue reactivity studies.51,52 Craving was assessed following
all acute beverage exposures and passive extinction periods. Cronbach’s αs
across all time points were 40.90. For ease of interpretation, percentage of
scale maximum was used in all analyses.
Alcohol use disorder diagnosis was determined via the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID).53 The SCID was
administered by trained Master’s-level clinicians and diagnoses were
determined via case review by the study clinicians and the supervising
licensed clinical psychologist (JM). A Timeline Followback54 was used to
determine both the drinks per week eligibility criteria (past 28 days) and
alcohol consumption during the study. The post-enrollment time windows
were from the ﬁrst session to the last and from the last session to the 3week follow-up. Acute withdrawal symptoms were assessed for eligibility
and at subsequent visits via the Clinical Withdrawal Assessment for
Alcohol–Revised.55 Side effects were assessed using the SAFTEE
Translational Psychiatry (2015), 1 – 8
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(Systematic Assessment of Treatment Emergent Events).56 Participants
completed the SAFTEE at the conclusion of each medication session and,
after session 1, participants completed the SAFTEE at the beginning of
each treatment session to report on any side effects during the interim
period. As a further measure of tolerability, participants were asked
whether they would participate in the study again and whether they
would recommend participation to friends during debrieﬁng. Process
coding for the treatment sessions was completed via a checklist of 28
dichotomous items was used to code the presence of speciﬁc elements
during the ﬁrst session, which was the most structured. In addition, the
GROMIT (Global Rating of Motivational Interviewing Therapist)57 was used
to assess whether the therapist were consistent with the spirit of
motivational interviewing for randomly selected subsequent sessions.
Coding was conducted by study therapists, but no therapists coded their
own sessions.

Data analysis
Potential differences between the two conditions were examined using
independent samples t-tests and χ2 tests for general characteristics, and a
2 (medication: DCS/PBO) × 2 (cue type: neutral/alcohol cues) mixed analysis
of variance to assess any differences in initial cue reactivity. The primary
analyses compared the effects of DCS versus PBO on subjective craving for
alcohol via 2 (medication: DCS/PBO) × 2 (cue type: neutral cues/alcohol
cues) mixed analyses of variance across the three bar laboratory exposures
occurring during treatment and one exposure at the 3-week follow-up.
Main effects and the interaction effect were examined to determine
whether DCS affected craving in general and cue-elicited craving in
particular. In addition, in the extinction sessions, we tested for the main
effects of DCS versus PBO on craving via 2 (medication: DCS/PBO) × 2
(extinction: post ﬁrst alcohol cues/post last alcohol cues) mixed analyses of
variance, examining both main effects and the interaction. This permitted
examining whether DCS affected the attenuation of craving over the
course of extinction. To examine effects of DCS on drinking, we conducted
one-way two-group analyses of covariance, covarying baseline drinking, on
drinking immediately following treatment and at the 3-week follow-up.
The continuous drinking variables were drinks per day, percent drinking
days and heavy drinking days. No missing data were present for the
primary outcome points and very rare for the follow-ups (see Participants);

no data were imputed. Tolerability was examined via frequencies of
symptoms on the SAFTEE, with χ2 tests to determine DCS/PBO differences.

RESULTS
Preliminary analyses
No signiﬁcant baseline differences were present between the two
groups (Table 1). During the cue reactivity screening, a signiﬁcant
effect of cue type was present (that is, changes from neutral to
alcohol cues; F(1,28) = 61.29, P o0.001), reﬂecting an increase in
craving; however, no medication condition effect was present (F
(1,28) = 0.03, P = 0.86) and no cue × medication interaction was
present (F(1,28) = 0.003, P = 0.96). Thus, at the start of the study,
participants exhibited robust alcohol cue reactivity, but the two
groups did not differ in the extent of this effect.
Process coding that follows pertains to the primary sample (that
is, participants who received both doses, n = 30). For the ﬁrst
session adherence, 87% of sessions were coded and the median
number of elements completed was 26 of 28 (93%), suggesting
high adherence. A total of 64 sessions were coded with the
GROMIT and the mean percent of scale maximum was high across
sessions: session 1—94%; session 2—93%; session 3—94%;
session 4—94%. In addition, the overall mean GROMIT score
was similarly high, 94%. This suggests that the content of the
intervention conformed to the spirit of motivational interviewing.
In addition, all participants were observed consuming the pill and
urine samples collected during the post-extinction period were
observed to ﬂuoresce, conﬁrming that the medication was
successfully administered.
At the conclusion of the study, 27 of the 30 participants
completed the debrieﬁng assessment. There were no differences
between groups in guessing medication or PBO condition
(χ2 = 0.06, P = 0.97): ‘Placebo,’ (DCS = 60%, PBO = 58%); ‘Active
Medication,’ DCS = 27%, PBO = 25%; ‘Unsure,’ DCS = 13%,
PBO = 17%.

Figure 1. Effects of D-cycloserine (DCS) and placebo on craving for alcohol during cue reactivity and extinction across the study protocol. The
DCS and placebo were administered 60 min before the cue exposure and extinction protocols in treatment (Tx) sessions 1 and 3. The initial
cue exposure protocol lasted 14 min, including assessments; the extinction protocol comprised 63 min of subsequent active and passive
exposure to personalized alcohol cues. Notations: horizontal bars with asterisks reﬂect signiﬁcant within-subjects (time) main effects for a
given interval; vertical bars with asterisks on the right reﬂect between-subjects (medication) main effects for the preceding epoch (including
both epoch during session 3); vertical lines with asterisks between two time points reﬂect a signiﬁcant difference in post hoc decomposition of
an interaction effect; *P ⩽ 0.05, **P ⩽ 0.01.
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(F(1,28) = 1.37, P = 0.25), nor was there a cue × medication interaction (F(1,28) = 0.96, P = 0.34, η2p = 0.03). During the extended
extinction period, there was a signiﬁcant effect of extinction
(F(1,28) = 11.53, P ⩽ 0.01, η2p = 0.29), reﬂecting a decrease in craving
across groups; a signiﬁcant effect of medication (F(1,28) = 5.15,
P ⩽ 0.05, η2p = 0.16), reﬂecting lower overall levels of craving for
individuals in the DCS condition; and a signiﬁcant extinction ×
medication interaction (F(1,28) = 4.04, P ⩽ 0.05, η2p = 0.13), reﬂecting an ampliﬁcation of extinction effects in the DCS condition.
Follow-up post hoc t-tests conﬁrmed no signiﬁcant difference
between groups immediately following alcohol cues, but a
signiﬁcant difference at the end of extinction. Means, standard
errors and statistical signiﬁcance are presented in Figure 1.
At session 3, the second medication administration, there was a
signiﬁcant effect of cue type (F(1,28) = 19.94, P ⩽ 0.01, η2p = 0.42),
indicating increased craving from neutral to alcohol cues across
groups, and a signiﬁcant medication effect (F(1,28) = 5.65, P ⩽ 0.05,
η2p = 0.17), indicating lower levels of craving in the DCS condition
compared with the PBO condition. The interaction effect was not
signiﬁcant (F(1,28) = 0.11, P = 0.74), suggesting similar increases in
craving following the presentation of alcohol cues in both groups.
During the extinction period, the DCS condition exhibited
generally lower craving (F(1,28) = 5.87, P ⩽ 0.05, η2p = 0.17), but
neither extinction (F(1,28) = 0.29, P = 0.60), nor the extinction × DCS
interaction (F(1,28) = 0.97, P = 0.33) were signiﬁcant, suggesting
that neither condition exhibited additional extinction and that the
DCS did not exert differential effects. Means, standard errors and
statistical signiﬁcance are in Figure 1.
At session 4, the results revealed a signiﬁcant effect of cue type
(F(1,26) = 9.07, P ⩽ 0.01, η2p = 0.25), reﬂecting increases in craving in
response to alcohol cues. The medication effect was also
signiﬁcant (F(1,26) = 5.60, P ⩽ 0.05, η2p = 0.17), revealing lower
craving in the DCS condition at both time points, but the
interaction was not signiﬁcant (F(1,26) = 0.04, P = 0.85). Means,
standard errors and statistical signiﬁcance are in Figure 1.
At the 3-week follow-up, parallel patterns were observed, with
signiﬁcant effects of cue type (F(1,26) = 7.33, P ⩽ 0.01, η2p = 0.22)
and medication (F(1,26) = 10.13, P ⩽ 0.05, η2p = 0.28), but no
interaction effect (F(1,26) = 1.10, P = 0.30). Means, standard errors
and statistical signiﬁcance are in Figure 1.

Figure 2. Effects of D-cycloserine (DCS) on short-term drinking
outcomes at the conclusion of treatment (Tx)and 3-week follow-up.
(a) Presents drinks per day, (b) presents percent drinking days
and (c) presents percent heavy drinking days. Baseline drinking is
covaried in all the analyses. *P ⩽ 0.05, **P ⩽ 0.01.

Effects of DCS on alcohol cue reactivity and extinction
During the ﬁrst medication session, a signiﬁcant effect of cue type
was present (F(1,28) = 9.33, P ⩽ 0.01, η2p = 0.25), reﬂecting a
signiﬁcant general increase in craving from neutral to alcohol
cues; however, a signiﬁcant medication effect was not observed

Effects on drinking and DCS tolerability
At the conclusion of treatment, participants who received DCS
reported signiﬁcantly fewer drinks per day (P ⩽ 0.05), percent
drinking days (P ⩽ 0.05) and percent heavy drinking days
(P ⩽ 0.01). However, none of the medication effects were
statistically signiﬁcant at 3-week follow-up (P = 0.25–0.62). These
outcomes are depicted in Figure 2.
Active medication was associated with minimal side effects. The
only notably higher side effect for DCS was drowsiness following
the second administration, which was not statistically signiﬁcant
(χ2 = 2.71, P = 0.10). Side effect frequencies are reported in Table 3.
A large majority of participants reported that they would
participate in the study again (89% yes, 4% not sure, 7% no)
and would recommend it to their friends (96% yes, 4% not sure).
The participant who would not participate again was in the
PBO condition.
DISCUSSION
The current study investigated whether two administrations of
50 mg DCS, provided in the context of treatment for individuals
with AUDs, would enhance extinction of cue-elicited alcohol
craving. A signiﬁcant DCS interaction was found during the ﬁrst
extinction session, with individuals in the active medication
condition exhibiting steeper decreases in craving during the
extinction period, and those group differences in craving persisted
Translational Psychiatry (2015), 1 – 8
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Table 3.

Tolerability of DCS and placebo
S1

Drowsy (%)
Dizzy (%)
Headache (%)
Slurred speech (%)
Tingling (%)
Mental confusion (%)
Irritability (%)
Anxiety (%)
Skin rash (%)
Aggression (%)

S2

S3A

S3B

S4

PBO

DCS

PBOaan = 13.

DCS

PBOa

DCS

PBO

DCS

PBOa

DCSbbn = 15.

21
14
0
0
0
0
0
0
0
0

19
0
0
0
0
0
0
6
0
0

8
8
23
0
0
0
31
8
0
15

13
0
6
0
0
13
13
0
6
0

0
0
8
0
0
8
8
8
0
0

6
6
0
0
0
0
0
0
6
0

7
7
0
0
0
0
0
0
0
0

31
0
0
0
0
0
0
0
0
0

15
0
15
0
0
0
15
8
0
0

0
0
0
0
0
0
0
0
0
0

Abbreviations: DCS, D-cycloserine; PBO, placebo; S1, 1 h following the ﬁrst medication administration; S2, intermediate session, ~ 3 days after the ﬁrst
administration; S3A, ~ 7 days after ﬁrst administration, S3B, 1 h following the second medication administration; S4, the fourth treatment session, ~1 week
following the second medication administration. Proportions represent participant endorsement of a symptom for a given time period. No signiﬁcant
differences in side effects were present between the two groups.

to the end of treatment and to a 3-week follow-up. Indeed, at the
3-week follow-up, participants in the DCS condition still exhibited
very low absolute levels of craving before and following exposure
to alcohol cues. A second dose of DCS was not found to
differentially enhance extinction to alcohol cues signiﬁcantly. This
suggests it may not have been necessary, although it is also
possible that it sustained the initial interaction effect. In addition,
compared with PBO, participants in the DCS condition drank less
while in treatment, although these differences were no longer
signiﬁcant at the follow-up. Across these ﬁndings, the DCS side
effect proﬁle was negligible, suggesting that the medication was
well tolerated by individuals with AUDs.
These ﬁndings suggest that pharmacological enhancement of
glutamatergic activity via the NMDA receptor increased the
extinction of cue-elicited craving for alcohol. These results are in
contrast to some previous human trials and number of factors
need to be considered in their interpretation. First, the current
study used a relatively small dose of DCS (50) when compared
with the two previous studies, which used 125 mg28 and 250
mg.30 Larger doses might have caused DCS to act as an NMDA
antagonist, leading to inhibition of extinction learning, and may
even have had psychoactive alcohol-like effects.58 Second, the
current study used a 1-week interval between extinction sessions,
whereas one of the previous studies used a minimum of 2 days,28
which might have resulted in DCS having antagonist
properties.37,38 Third, this study required participants to exhibit
cue-elicited craving as an eligibility criterion. Importantly, none of
the previous studies established cue reactivity in their participants
in advance of enrollment. Therefore, some of the participants in
previous studies may not have exhibited increases in craving that
were sufﬁciently large enough to be subsequently extinguished.
Indeed, Watson et al.30 reported that approximately half of their
sample exhibited no reactivity to the alcohol cues. This is
particularly important because the level of initial cue-elicited
craving fundamentally determines how much extinction of that
craving is observable. Furthermore, the sample sizes in all of the
studies to date have been relatively small and only a few nonreactors could substantially affect the ﬁndings.
It was also notable that the current study used a treatmentseeking clinical sample who received the medication and
extinction in the context of outpatient treatment. Two of the
previous studies used analogue samples of non-treatment-seeking
heavy drinkers28,29 and one previous study used an aftercare
clinical sample but the experimental procedures were not framed
as part of treatment.30 In this way, the current study is most similar
to the study by Santa Ana et al.,59 which found 50 mg DCS
Translational Psychiatry (2015), 1 – 8

signiﬁcantly enhanced extinction among treatment-seeking nicotine-dependent outpatients. Thus, it appears that DCS enhances
extinction to alcohol and tobacco cues when administered to
clinical samples in the context of treatment according to speciﬁc
dosing and administration parameters. This is also consistent with
the anxiety disorders literature, suggesting that DCS enhances
extinction in clinical samples seeking treatment,18,20–22 but not
analogue samples using de novo anxiety paradigms,41,42 and only
when the exposure procedures are successful.60,61 The reason for
signiﬁcant effects in clinical sample may be due to the range of
responses to environmental cues. Clinical severity is signiﬁcantly
associated with cue reactivity62 and thus clinical patients are more
likely to exhibit robust cue-elicited craving. This, in turn,
determines both how much extinction can be observed and the
extent to which it can be enhanced.
More speculatively, it is possible that positive effects are
observed when DCS is administered as part of treatment protocols
for other reasons. It may be that the new learning that is taking
place in the context of treatment is not simply the attenuation of
the associative memory structure, but enhancement of other
declarative forms of learning. For example, patients may
experience enhancement of the strategies used for coping with
cravings or may more deeply learn self-efﬁcacy for experiencing
cravings and not drinking. The current study cannot address these
possibilities, but future studies should try to disentangle DCS
effects on lower-order and higher-order learning processes.
It is important to consider these ﬁndings in the context of the
study’s strengths and weaknesses. With regard to strengths, the
study emphasized high internal validity and met the recommended parameters of investigating DCS to enhance extinction.
However, although the study was one of the largest on DCS and
cue-elicited craving for alcohol, it still was relatively small in
absolute size. In addition, as a proof-of-concept study on in vivo
craving and extinction, the follow-up period was relatively short,
only two administrations were used, and only one dose of DCS
was used. Although conventional notions of reaching steady state
drug levels do not apply to DCS, future studies should particularly
examine a protracted administration schedule to observe maximal
learning enhancement. Nonetheless, although the study was not
designed or powered as a formal test of the medication’s clinical
efﬁcacy, the signiﬁcant positive short-term effects on drinking in
this small sample suggest that positive long-term effects may be
present in an appropriately powered clinical trial with a larger
number of doses. Ideally, future studies will combine the putative
mechanisms discussed above with clinical outcome measures to
both address efﬁcacy and, if present, clarify the operative
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underlying learning mechanisms. It is also worth noting that even
though very high internal validity, including a sample with no
psychiatric comorbidities whatsoever, is desirable in an early-stage
proof-of-concept study, the current study permitted smokers as
participants. However, this was based on the very high prevalence
of smoking among individuals with AUDs63 and excluding
smokers was considered too signiﬁcant a threat to the external
validity of the study. Whether smoking status is systematically
related to DCS outcomes will be worth exploring in future studies.
More broadly, an important consideration is the role of context
speciﬁcity in extinguishing cue-elicited craving. There is extensive
experimental evidence that extinction is not ‘unlearning,’ but new
learning about the context dependency of environmental
contingencies.64 For example, in animal models, it has been
robustly demonstrated that for initial associative conditioning in
one context, when extinction takes place in a different context, it
does not generalize back to the ﬁrst. Applied to extinction-based
clinical interventions, context speciﬁcity is believed to substantially undermine the generalizability of in-session extinction to a
patient’s day-to-day environment and is putatively responsible for
the modest clinical beneﬁts of CET to date. Thus, even if DCS
enhances extinction in treatment, it is not clear if it will enhance
the generalizability of extinction beyond the treatment setting,
potentially limiting its real-world clinical utility.
Despite this, there are some reasons to think DCS has clinical
promise. To start, the current results revealed positive short-term
beneﬁts with two administrations in a relatively small sample. In
addition, as noted earlier, trials of CET for alcohol dependence
have reported modest positive outcomes,15 suggesting there is a
baseline positive signal that is viable for enhancement and
maximization. Similarly, human laboratory studies of cue-elicited
craving in multiple contexts suggest that substantial generalizability does in fact take place43,52 and again would be the target
of maximization by DCS. Finally, it is possible that DCS enhances
the declarative learning processes discussed above and those
higher-order relationships would be expected to generalize
beyond the immediate treatment context. However, we recognize
that this is conjecture. Alternatively, it is also possible that the
current ﬁndings may only contribute to understanding the
neurobiology of cue-elicited craving and that, because of the
context dependency of extinction learning, DCS may have limited
clinical utility. This is, of course, fundamentally an empirical
question and one that needs to be addressed in future clinical
investigations. The current results provide a strong basis for
pursuing these questions further.
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